Louisiana State Employees Retirement System increased its position in shares of Zoetis Inc (NYSE:ZTS) by 0.4% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 25,300 shares of the company’s stock after buying an additional 100 shares during the period. Louisiana State Employees Retirement System’s holdings in Zoetis were worth $2,547,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Farmers & Merchants Trust Co of Chambersburg PA acquired a new position in Zoetis during the 1st quarter worth $25,000. Cobiz Wealth LLC raised its holdings in shares of Zoetis by 3.3% in the 1st quarter. Cobiz Wealth LLC now owns 55,893 shares of the company’s stock worth $5,649,000 after purchasing an additional 1,803 shares in the last quarter. CAPROCK Group Inc. bought a new stake in shares of Zoetis in the 1st quarter worth approximately $209,000. Mercer Global Advisors Inc. ADV bought a new stake in shares of Zoetis in the 1st quarter worth approximately $2,082,000. Finally, Valeo Financial Advisors LLC raised its holdings in shares of Zoetis by 12.6% in the 1st quarter. Valeo Financial Advisors LLC now owns 3,379 shares of the company’s stock worth $340,000 after purchasing an additional 377 shares in the last quarter. 90.93% of the stock is currently owned by hedge funds and other institutional investors.

ZTS traded up $0.02 on Monday, reaching $101.69. 14,530 shares of the company traded hands, compared to its average volume of 1,884,614. Zoetis Inc has a 52-week low of $77.00 and a 52-week high of $103.33. The company has a market capitalization of $48.43 billion, a PE ratio of 32.50, a PEG ratio of 1.83 and a beta of 0.93. The company has a debt-to-equity ratio of 2.95, a quick ratio of 2.46 and a current ratio of 3.60.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 14th. The company reported $0.79 EPS for the quarter, beating the Zacks’ consensus estimate of $0.77 by $0.02. Zoetis had a net margin of 24.51% and a return on equity of 73.85%. The firm had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.53 billion. During the same period in the previous year, the firm posted $0.69 earnings per share. The firm’s revenue was up 7.1% on a year-over-year basis. On average, equities analysts forecast that Zoetis Inc will post 3.46 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 3rd. Investors of record on Thursday, April 18th will be given a dividend of $0.164 per share. This represents a $0.66 dividend on an annualized basis and a yield of 0.65%. The ex-dividend date of this dividend is Wednesday, April 17th. Zoetis’s payout ratio is presently 21.09%.

ZTS has been the topic of several analyst reports. Zacks Investment Research downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Sunday, January 6th. UBS Group initiated coverage on shares of Zoetis in a research report on Wednesday, January 23rd. They issued a “neutral” rating and a $86.00 target price on the stock. BMO Capital Markets lifted their target price on shares of Zoetis from $93.00 to $101.00 and gave the stock a “market perform” rating in a research report on Monday, February 25th. Stifel Nicolaus raised shares of Zoetis from a “hold” rating to a “buy” rating and lifted their target price for the stock from $97.00 to $110.00 in a research report on Monday, March 4th. Finally, SunTrust Banks initiated coverage on shares of Zoetis in a research report on Tuesday, March 19th. They issued a “hold” rating and a $100.00 target price on the stock. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $100.57.

In other Zoetis news, CEO Juan Ramon Alaix sold 312,109 shares of the business’s stock in a transaction that occurred on Thursday, February 28th. The shares were sold at an average price of $94.06, for a total value of $29,356,972.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Roxanne Lagano sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $101.89, for a total transaction of $203,780.00. Following the completion of the sale, the insider now directly owns 30,727 shares of the company’s stock, valued at $3,130,774.03. The disclosure for this sale can be found here. Insiders have sold 404,209 shares of company stock worth $38,052,349 over the last ninety days. 0.35% of the stock is currently owned by insiders.

WARNING: “Louisiana State Employees Retirement System Has $2.55 Million Position in Zoetis Inc (ZTS)” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://theolympiareport.com/2019/04/15/louisiana-state-employees-retirement-system-has-2-55-million-position-in-zoetis-inc-zts.html.

Zoetis Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

See Also: Mutual Funds

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.